CompletedPhase 2NCT04614779
Long-term Clinical Study of CN128 in Thalassemia Patients
Studying Rare hereditary hemochromatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hangzhou Zede Pharma-Tech Co., Ltd.
- Principal Investigator
- Jianmin Jianmin, PhDFirst Affiliated Hospital of Guangxi Medical University
- Intervention
- CN128 Tablets(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 16-60 years · All sexes
- Timeline
- 2020 – 2022
Study locations (1)
- The First Affiliated Hospital Of Guangxi Medical University, Nanning, Guangxi, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04614779 on ClinicalTrials.govOther trials for Rare hereditary hemochromatosis
Additional recruiting or active studies for the same condition.